300558.SZ SHZ
Betta Pharmaceuticals Co., Ltd.
1W: -0.5%
1M: +0.0%
3M: -24.9%
YTD: +5.6%
1Y: -25.1%
3Y: +0.2%
5Y: -50.6%
¥50.48 ($7.53)
+1.52 (+3.10%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Balance Sheet Trends
Total Assets
$9.3B
+2.1% ▲
5Y CAGR: +17.7%
Total Liabilities
$3.7B
-3.2% ▼
5Y CAGR: +17.2%
Shareholders Equity
$5.6B
+6.1% ▲
5Y CAGR: +17.8%
Cash & Investments
$598M
-20.5% ▼
5Y CAGR: +2.8%
Total Debt
$1.7B
-31.9% ▼
5Y CAGR: +20.8%
Net Debt
$1.2B
-29.4% ▼
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $1.3B | $792M | $731M | $752M | $472M |
| Short-Term Investments | $0 | $201M | $0 | $540K | $126M |
| Cash & ST Investments | $1.3B | $993M | $731M | $753M | $598M |
| Net Receivables | $59M | $173M | $523M | $286M | $100M |
| Inventory | $189M | $293M | $372M | $328M | $290M |
| Other Current Assets | $11M | $123M | $179M | $159M | $191M |
| Total Current Assets | $1.8B | $1.7B | $1.7B | $1.5B | $1.2B |
| Property, Plant & Equip. | $776M | $1.3B | $2.1B | $2.6B | $3.0B |
| Goodwill & Intangibles | $2.2B | $2.8B | $3.1B | $3.6B | $3.6B |
| Long-Term Investments | $312M | $145M | $952M | $1.4B | $1.3B |
| Other Non-Current Assets | $51M | $239M | $7M | $0 | $168M |
| Total Non-Current Assets | $3.4B | $4.6B | $6.2B | $7.6B | $8.1B |
| Total Assets | $5.2B | $6.3B | $7.9B | $9.1B | $9.3B |
| — Liabilities — | |||||
| Accounts Payable | $114M | $431M | $591M | $800M | $746M |
| Short-Term Debt | $0 | $0 | $1.1B | $602M | $100M |
| Deferred Revenue | $3M | $452M | $4M | $0 | $0 |
| Other Current Liabilities | $322M | $5M | $275M | $397M | $691M |
| Total Current Liabilities | $438M | $889M | $2.1B | $1.8B | $1.8B |
| Long-Term Debt | $0 | $0 | $656M | $1.8B | $1.6B |
| Other Non-Current Liab. | $519M | $622M | $0 | $0 | $69M |
| Total Non-Current Liabilities | $647M | $697M | $848M | $2.0B | $1.8B |
| Total Liabilities | $1.1B | $1.6B | $3.0B | $3.8B | $3.7B |
| — Equity — | |||||
| Common Stock | $413M | $415M | $417M | $418M | $418M |
| Retained Earnings | $1.7B | $1.9B | $2.0B | $2.3B | $2.6B |
| Accumulated OCI | $403M | $467M | $600M | $594M | $585M |
| Total Stockholders Equity | $4.1B | $4.6B | $4.8B | $5.3B | $5.6B |
| Total Liabilities & Equity | $5.2B | $6.3B | $7.9B | $9.1B | $9.3B |
| — Key Metrics — | |||||
| Total Debt | $535M | $11M | $1.8B | $2.4B | $1.7B |
| Net Debt | -$811M | -$781M | $1.0B | $1.7B | $1.2B |
| Total Investments | $312M | $346M | $952M | $1.4B | $1.4B |